Annual Secretarial Compliance Report for the financial Year ended on 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has submitted its Annual Secretarial Compliance Report for FY 2024-25, filed under SEBI Regulation 24A(2). The Practicing Company Secretary (Nilesh Shah & Associates) reviewed the company's filings, website, and records and confirmed overall compliance with SEBI regulations and circulars. All key areas — Secretarial Standards, policy adoption and updates, website disclosures, director eligibility, document preservation, board performance evaluation, related party transactions, event disclosures, and insider trading — were marked compliant. One minor observation was noted: the company filed revised shareholding patterns for the June 2024 quarter in response to a BSE query, though the original filing was within prescribed timelines. No actions were taken by SEBI or stock exchanges against the company, its promoters, or directors during the review period.
This is a routine annual regulatory filing and broadly positive from a governance standpoint, confirming no major non-compliances. The minor filing delay and prior-year insider trading penalty (₹10,000 fine plus warning to a promoter group member in July 2023) are immaterial. Investors should view this as a neutral to mildly positive signal about the company's compliance discipline.